Intellia Therapeutics Stock Discussion

Insiders selling shares at low prices may signal expected stock weakness. The absence of insider buying and increased selling over the past year suggest the shares aren't cheap, making the company a cautious investment.

The first treatment based on CRISPR technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors.
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...

The future prospects of the company following disappointing price downfall despite revenue growth are now crucial. Long-term investors, however, made a 6% return each year if invested over five years, suggesting previous over-hype.

According to the 13F report submitted by ARK Investment Management Company under Cathie Wood, the top five holdings in the first quarter were Tesla, ROKU, Zoom, Coinbase, and UiPath. Among them, the holdings of Tesla increased by 17%. Coinbase increased its holdings by nearly 2.56 million shares. In addition, in the first quarter, ARK built positions in 6 stocks including AMD and Pinterest, and cleared positions in 17 stocks such as Weilai Automobile and Silvergate; and increased its holdings in...